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Abstract
Background: To demonstrate how the Observational Healthcare Data Science and Informatics (OHDSI)
collaborative network and standardization can be utilized to scale-up external validation of patient-level prediction
models by enabling validation across a large number of heterogeneous observational healthcare datasets.
Methods: Five previously published prognostic models (ATRIA, CHADS2, CHADS2VASC, Q-Stroke and Framingham)
that predict future risk of stroke in patients with atrial fibrillation were replicated using the OHDSI frameworks. A
network study was run that enabled the five models to be externally validated across nine observational healthcare
datasets spanning three countries and five independent sites.
Results: The five existing models were able to be integrated into the OHDSI framework for patient-level prediction
and they obtained mean c-statistics ranging between 0.57–0.63 across the 6 databases with sufficient data to
predict stroke within 1 year of initial atrial fibrillation diagnosis for females with atrial fibrillation. This was
comparable with existing validation studies. The validation network study was run across nine datasets within 60
days once the models were replicated. An R package for the study was published at https://github.com/OHDSI/
StudyProtocolSandbox/tree/master/ExistingStrokeRiskExternalValidation.
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Conclusion: This study demonstrates the ability to scale up external validation of patient-level prediction models
using a collaboration of researchers and a data standardization that enable models to be readily shared across data
sites. External validation is necessary to understand the transportability or reproducibility of a prediction model, but
without collaborative approaches it can take three or more years for a model to be validated by one independent
researcher. In this paper we show it is possible to both scale-up and speed-up external validation by showing how
validation can be done across multiple databases in less than 2 months. We recommend that researchers
developing new prediction models use the OHDSI network to externally validate their models.
Keywords: Patient-level prediction, Prognostic model, External validation, Transportability, Collaborative network
Key points
 External validation of patient-level prediction models
is necessary for understanding generalizability of
models but validation generally takes three or more
years [1]
 We demonstrate that the Observational Healthcare
Data Science and Informatics (OHDSI) network and
standardizations enable external validation to be
completed across multiple sites and countries in
days
 We hope other researchers will utilize the OHDSI
network to externally validate new and existing
patient-level prediction models
Background
Observational healthcare data often contains longitu-
dinal medical records for large heterogeneous popula-
tions. There has been increased interest in learning
patient-level prediction models using these big real-
world datasets with the aim of improving healthcare [2].
These patient-level prediction models can be used to
identify high-risk subgroups that could benefit from in-
terventions. For example, the cardiovascular model
QRISK2, that was developed using a UK primary care
database, is used to identify patients who may benefit
from lipid -lowering medication [3]. It is important to
ensure a model has good performance before it is used
clinically and this requires external validation [2, 4].
Models are often internally validated using the devel-
opment dataset by withholding a subset of that data
from the model training stage so that it can be used for
evaluating the model performance. The majority of
patient-level prediction models will report internal valid-
ation. External validation is accomplished by evaluating
the model on a new dataset (that is different from the
development dataset). Few published patient-level pre-
diction models are externally validated, and research has
shown that it often takes three or more years for exter-
nal validation to occur once a model is published [1].
External validation of a patient-level prediction model
can provide useful insights into the accuracy of the
model across different patient characteristics and may be
used to learn the impact of missing predictors. The type
of external validation depends on the similarity between
the development and validation datasets. When a model
is validated on a population that has similar characteris-
tics to the development data population the
‘generalizability performance’ of the model is investi-
gated (i.e., how well the model performs when making
predictions on similar patients). When a model is vali-
dated on a population that has different characteristics
to the development data population the ‘transportability
performance’ of the model is investigated (i.e., how well
the model performs on different patients). Many obser-
vational datasets are not representative of the whole
population, so the transportability performance of the
model discovered during external validation on patients
with different characteristics is important to know when
identifying who the model can be broadly applied to. For
example, some clinical guidelines recommend treatment
stratification for patients based on applying a simple risk
score model that was developed on a small population
but the transportability of the model to the general
population may not have been studied. This may lead to
incorrect predictions.
External validation is a slow process due to the diffi-
culty finding suitable data to replicate a prediction
model on and difficulty replicating a prediction model
(e.g., writing code to correctly extract the same model
covariates from the new data). Published papers often
lack the information required to replicate the model or
can be interpreted subjectively (e.g., in defining medical
conditions or variables) which can be an issue causing
models to be replicated incorrectly. This prevents effi-
cient and large-scale external validation which likely
slows down clinical uptake of published patient-level
prediction models or results in the models being applied
clinically to patient populations where the model trans-
portability is unknown.
A collaborative approach to external model validation
has been proposed to enable extensive evaluation of pre-
diction models [5]. The Observational Healthcare Data
Science and Informatics (OHDSI) network is a
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community of researchers that are working towards the
common goal of improving the analysis of observational
data [6]. The OHDSI community have developed stan-
dardizations that enable efficient collaboration across re-
search sites. The main standardization is the common
data structure and vocabulary used by all collaborators
known as the Observational Medical Outcomes Partner-
ship (OMOP) common data model. The OMOP com-
mon data model ensures all researchers have their data
in the same structure so analysis codes such as Struc-
tured Query Language (SQL) can be shared across sites.
This has enabled the development of analysis packages
in R for causal inference and patient-level prediction [7]
that can be used by any researcher with data in the
OMOP common data model. The OHDSI collaborative
network, common data model and patient-level predic-
tion package now present the opportunity to scale up
external validation.
The aim of this study is to demonstrate that the
OHDSI tools and OMOP common data model can be
used by researchers to investigate the external validation
performance of their prediction models across a large
number of heterogeneous patient populations. Instead of
taking years to externally validate a model, OHDSI may
make it possible to apply a prediction models to a large
number of datasets in a short period of time. To demon-
strate this we selected the prediction problem of 1-year
risk of stroke in newly diagnosed atrial fibrillation pa-
tients as there are multiple existing models that are used
clinically, namely Anticoagulation and Risk Factors in
Atrial Fibrillation (ATRIA) (no prior stroke model) [8],
Framingham (no prior stroke model) [9], Congestive
heart failure, Hypertension, Age > 75, Diabetes, prior
Stroke/transient ischemic attack (CHADS2) [10],
CHADS2-VASc [11] and Q-Stroke (female model) [12].
We show these models can be replicated using the
OHDSI standardizations and externally validated across
numerous data sites within the OHDSI network.
Methods
Existing stroke prediction models
We selected the problem of predicting stroke in patients
with atrial fibrillation as it has been well studied and is
one of the only prediction problems to have been exten-
sively validated. Therefore, we have ample benchmarks
to compare to the results of this study. The existing
models we replicated were ATRIA, CHADS2, CHA2DS2
−VASc, Framingham and Q-Stroke.
The ATRIA [8] model was developed on a cohort of
7284 patients who were 18+ and had an atrial fibrillation
outpatient diagnosis during 1997 or 1998. ATRIA was
internally validated on a 3643 patient hold out set
obtaining a c-statistic of 0.72. In the same paper, the au-
thors also externally validated the model on a cohort of
33,247 patients aged 21+ with inpatient or outpatient
atrial fib or flutter during 2006–2009, obtaining a c-
statistic of 0.7. The CHADS2 score [10] was developed
by combining two other stroke prediction models (using
the variables from these models and assigning points)
and was validated on 1733 patients aged 65 to 95 years
who had nonrheumatic atrial fibrillation. The CHADS2
score obtained a c-statistic of 0.81 on this population.
The CHA2DS2−VASc score [11] is another score-based
model that was developed using knowledge of risk fac-
tors. The model was validated on a cohort of 1577 pa-
tients who were 18+ and had atrial fibrillation during
2003 to 2004 from 35 countries. The model obtained a
c-statistic of 0.61 for this patient population. The Fra-
mingham score [9] model was based on a Cox model de-
veloped using data from 705 patients aged 55 to 94 with
initial atrial fibrillation. The internal validation, using a
bootstrap approach, showed a c-statistic of 0.66. The Q-
Stroke [12] model was developed using primary care
data from the UK consisting of 3, 549, 478 patients aged
25–84 with no prior stroke or anticoagulation use (ex-
cept aspirin) and was internally validated on 1, 897, 168
similar patients. When applying the model to predict the
10-year risk of stroke in female patients with atrial fibril-
lation at baseline, the c-statistic was 0.65.
The existing models include a small number of vari-
ables, Table 1 summarizes the variables included in each
model. Some of the variables are unlikely to be available in
claims data and these are marked with the + symbol. A
large number of Q-Stroke variables are not commonly re-
corded in claims data (or are UK specific), so this model is
difficult to replicate in external non-UK databases. For ex-
ample, US claims data contain incomplete measurement
records and rarely record family history but many of the
Q-stroke predictors were recent measurements or family
history. Table 2 presents the internal performance and
published external validation performance for the five
models. Although the internal validation c-statistic for
some of the models was as high as 0.8, independent exter-
nal validation studies of the models tend to show the
models achieve c-statistics between 0.6 and 0.7.
The complete definitions for each variable (sets of
SNOMED CT or RXNorm codes) are provided in
Additional file 1.
Validation prediction task
Within a target population of female patients with newly
diagnosed atrial fibrillation and no prior stroke predict
who will develop a stroke 1 to 365 days after initial diag-
nosis of atrial fibrillation.
Sources of data
We validated the existing models using a retrospective
cohort design and various observational healthcare
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datasets (e.g., claims data and electronic healthcare data).
The datasets used to evaluate the models are:
IBM MarketScan® Commercial Database (CCAE) is a
United States employer-sponsored insurance health
plans claims database. The database contains claims (e.g.
inpatient, outpatient, and outpatient pharmacy) from
private healthcare coverage to employees, their spouses,
and dependents, so patients are aged 65 or younger. The
database contains data collected between 2000 and 2018.
IBM MarketScan® Medicare Supplemental Database
(MDCR) represents health services of retirees in the
United States with primary or Medicare supplemental
coverage through privately insured fee-for-service, point-
of-service, or capitated health plans. The patients are
aged 65 or older. The database contains data collected
between 2000 and 2018.
IBM MarketScan® Multi-State Medicaid Database
(MDCD) contains adjudicated US health insurance
Table 1 The covariates included in ATRIA, Framingham, CHADS2, CHA2DS2VASc and Q-Stroke
Predictor ATRIA Framingham CHADS2 CHA2DS2VASc Q-Stroke
Age >= 85 x
Age 75–84 x
Age 65–74 x x
Age 60–62 x
Age 63–66 x
Age 67–71 x
Age 72–74 x
Age 75–77 x
Age 78–81 x
Age 82–85 x
Age 86–90 x
Age 91–93 x
Age > 93 x
Age >= 75 x x
Female x x x
Diabetes x x x x x
Congestive heart failure x x x
Prior Stroke or transient ischemic attack x x x
Hypertension x x x x
Systolic blood pressure+ x x
Total cholesterol: HDLa cholesterol ratio+ x
Townsend deprivation score+ x
Proteinuria x
eGFRa < 45 or End stage renal disease x
Vascular disease x
Congestive heart failure or Liver disease x
Smoking status+ x
Ethnicity+ x
Coronary heart disease x
Family history of congestive heart failure+ x
Atrial fibrillation x
Rheumatoid arthritis x
Chronic renal disease x
Valvular heart disease x
Existing models for predicting stroke risk. + indicates predictors are often poorly recorded or missing in claims data
a HDL High-density lipoproteins, eGFR Estimated glomerular filtration rate
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claims for Medicaid enrollees from multiple states and
includes hospital discharge diagnoses, outpatient diagno-
ses and procedures, and outpatient pharmacy claims as
well as ethnicity. The database contains data collected
between 2006 and 2018.
Optum© De-Identified Clinformatics® Data Mart Data-
base – Socio-Economic Status (Optum Claims) is an ad-
judicated administrative health claims database for
members with private health insurance. The population
is primarily representative of US commercial claims pa-
tients (0–65 years old) with some Medicare (65+ years
old) however ages are capped at 90 years. The database
contains data collected between 2000 and 2018.
Optum© de-identified Electronic Health Record Data-
set (Optum EHR) is a US electron health record contain-
ing clinical information, inclusive of prescriptions as
prescribed and administered, lab results, vital signs, body
measurements, diagnoses, procedures, and information
derived from clinical Notes using Natural Language Pro-
cessing (NLP). The database contains data collected be-
tween 2006 and 2018.
Stanford Translational Research Integrated Database
Environment (STRIDE) is a clinical data warehouse that
supports clinical and translational research at Stanford
University. This resource includes the EHR data of ap-
proximately 2 million adult and pediatric patients cared
for at either the Stanford Hospital or the Lucile Packard
Children’s hospital. This study was completed on an
OMOP-CDM adherent instance of STRIDE. The data-
base contains data collected between 2000 and 2018.
Columbia University Medical Center’s (CUMC) data
come from New York Presbyterian hospital’s clinical
data warehouse. The database comprises EHR data on
approximately 5 million patients and includes informa-
tion such as diagnoses, procedures, lab measurements
and prescriptions. The database contains data collected
between 1980 and 2018.
Ajou University School Of Medicine (AUSOM) is a
database containing the entire EHR data from 1994 to
2018 of Korean tertiary hospital, Ajou university hos-
pital. It contains medical record of about 2.9 million
patients. The database contains data collected between
1994 and 2018.
The Integrated Primary Care Information (IPCI) is an
electronic health care database containing patients of
Dutch general practitioners (primary care). The database
contains data collected between 1996 and 2018.
Each site had institutional review board approval for
the analysis, or used deidentified data and thus the ana-
lysis was determined not to be human subjects research
and informed consent was not deemed necessary at any
site.
Participants
The existing models were applied to two target popula-
tions. Both target populations consisted of female pa-
tients newly diagnosed with atrial fibrillation and no
prior stroke or anticoagulant use but target population 1
was patients aged 65 to 95 and target population 2 was
all ages.
Target population 1: The target populations was de-
fined as females aged 65–95 with either:
 2 atrial fibrillation records
 1 atrial fibrillation in an inpatient setting
 1 atrial fibrillation with an electrocardiogram (ECG)
within 30 days prior
and at least 730 days prior database observation and no
prior stroke and no prior anticoagulant.
Target population 2: The target populations was de-
fined as females with either:
 2 atrial fibrillation records
 1 atrial fibrillation in an inpatient setting
 1 atrial fibrillation with an ECG within 30 days prior
and at least 730 days prior database observation and no
prior stroke and no prior anticoagulant.
The target populations may contain different types of
patients per database (e.g., different country US, Euro-
pean or Asian patients and different types of records
such as inpatient and outpatient). The different
Table 2 The internal and external validation performances of the existing stroke prediction models
ATRIA Framingham CHADS2 CHA2DS2VASc Q-Stroke
Internal c-statistic 0.72 0.66 0.82 0.61 0.65
External c-statistic
UK Electronic Medical Records (EMR) 2015 [13] 0.7 (0.69–0.71) – 0.68 (0.67–0.69) 0.68 (0.67–0.69) –
Swedish EMR 2016 [14] 0.71 (0.70–0.71) – 0.69 (0.69–0.70) 0.69 (0.69–0.70) –
Taiwan 2016 [15] – – 0.66 0.70 –
New Zealand, Russia and the Netherlands 2014 [16] – 0.70 (0.68–0.73) – – 0.71 (0.69–0.73)
UK EMR 2010 [17] – 0.65 (0.63–0.68) 0.66 (0.64–0.68) 0.67 (0.65–0.69) –
Internal and previously published external model fit statistics for each of the five models that predict stroke in atrial fibrillation patients
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databases used in this study are detailed in section
‘Sources of data’.
Outcome
We predicted stroke occurring 1 day until 365 days after
the initial atrial fibrillation start date. The stroke out-
come was defined as:
 An ischemic or hemorrhagic stroke recorded with
an inpatient or ER visit
The code sets used to define atrial fibrillation, ECG
and ischemic or hemorrhagic stroke are presented in
Additional file 2. The full analysis code (data creation
and model evaluation) is available at: https://github.com/
OHDSI/StudyProtocolSandbox/tree/master/
ExistingStrokeRiskExternalValidation
Sensitivity analysis
Patients with a high risk of future stroke are often given
anticoagulants as a preventative. If a high-risk patient is
given an anticoagulant intervention during the 1-year
time-at-risk this may prevent the stroke. We therefore
performed a sensitivity analysis to remove patients who
had an anticoagulant during the 1-year time-at-risk that
may have prevented a stroke. For the sensitivity analysis,
the target populations were modified by censoring pa-
tients at the point an anticoagulant was recorded, so any
patient with an anticoagulant during the time-at-risk
period was effectively removed from the target popula-
tion unless they had a stroke prior to the anticoagulant.
Predictors
We calculated existing model predictors using pheno-
type definitions specified in the paper describing the de-
velopment of the model when provided. If the
development paper did not provide a definition, we used
our own. The definitions for each predictor can be found
in Additional file 1.
Missing data
Age and gender are required by the OMOP common
data model used by OHDSI and will never be missing.
For each condition (diabetes, chronic heart failure,
stroke, hypertension, proteinuria, end stage renal disease
(ESRD), vascular disease, liver disease, coronary heart
disease (CHD), atrial fibrillation, rheumatoid arthritis,
chronic renal disease and valvular heart disease), we
considered no records of the condition in the database
to mean the patient does not have the condition. Ethni-
city is often missing completely from a database and
when missing we did not include it. Smoking status and
family history are rarely recorded in claims data, we im-
puted 0 (never smoker and no family history) when the
predictor was missing. Townsend deprivation score is
specific to the UK and was not included as a predictor
in our validation. The blood pressure and cholesterol
measurements are rarely recorded in claims data and
were not included as predictors in our validation.
Statistical analysis
The prediction model performances were evaluated
using the area under the receiver operating characteristic
(AUROC) curve which is equivalent to the c-statistic for
binary classification. Confidence intervals were also cal-
culated when the number of outcome patients was fewer
than 1000. As the models are being used to predict 1-
year risk in diverse patients we recalibrated the models
for each database. The models were recalibrated by fit-
ting a linear model to the predicted scores to learn a
database specific intercept and gradient. We present the
calibration plots for each of the five models recalibrated
in each of the datasets. For each decile we calculate the
mean recalibrated predicted risk and plot against the ob-
served fraction of patients who have the outcome.
Development vs validation
We picked participants that matched all eligibility cri-
teria for all 5 existing models being validated but this
may be a subset of the patient population used to de-
velop the model for many of the models. Many of the
predictors for the Q-stroke model were not available in
our data and the measurements for Framingham were
also no available. The outcome in this validation study
was 1 year following index but many of the models were
developed for 10-year risk.
Results
Participants
The characteristics of the participants across the net-
work showed that hypertension was very common in the
patients. Patients were older and often has renal and car-
diac issues. See Additional file 3 for the full characteris-
tic table.
IPCI did not contain inpatient stroke records, so the
models were unable to be evaluated on this dataset. The
percentage of patients who had stroke recorded within
1 year in each of the remaining dataset target popula-
tions is presented in Table 3. The percentage of patients
with stroke during the 1 year following atrial fibrillation
diagnosis in the various target populations ranged from
approximately 1% in CCAE, STRIDE, AUSOM and
Optum EHR to 5% in MDCD and CUMC.
Model performance
The results of the discriminative ability of the five exist-
ing models across all eight datasets that had inpatient
stroke recorded are presented in Table 4. As the
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AUSOM and STRIDE datasets had outcome counts less
than 100, we report the performance in Table 4 but do
not include it in the aggregate summaries due to uncer-
tainty in the estimates as a result of small sample sizes.
Across the datasets with sufficient outcome counts,
ATRIA obtained a mean AUROC of 0.61 (range 0.57–
0.64) on the female patients aged 65 or older and a mean
AUROC of 0.63 (range 0.58–0.66) on the female patients
of all ages. CHADS2 obtained a mean AUROC of 0.58
(range 0.54–0.60) on the female patients aged 65 or
older and a mean AUROC of 0.61 (range 0.56–0.63) on
the female patients of all ages. CHA2DS2VASc obtained
a mean AUROC of 0.60 (range 0.55–0.62) on the female
patients aged 65 or older and a mean AUROC of 0.63
(range 0.58–0.65) on the female patients of all ages. Fra-
mingham obtained a mean AUROC of 0.60 (range 0.56–
0.63) on the female patients aged 65 or older and a mean
AUROC of 0.64 (range 0.57–0.65) on the female patients
of all ages. Q-Stroke obtained a mean AUROC of 0.55
(range 0.53–0.56) on the female patients aged 65 or
older and a mean AUROC of 0.57 (range 0.54–0.61) on
the female patients of all ages.
The calibration plots showed that recalibrating the
total scores using a linear model appears to work for
ATRIA, Q-stroke, CHADS2 and CHA2DS2VASc but the
Framingham model may need a non-linear recalibration
as it appeared to under-estimate risk in the middle risk
groups, see Additional file 4.
Discussion
This study demonstrated the ability to perform external
validation across five different data sites with access to
nine databases in a short period of time. The countries
corresponding to each database spanned across the
USA, Europe and Asia. This shows the OHDSI network
and tools can be used by researchers to efficiently per-
form external validation of models developed using
observational healthcare data. The datasets used for val-
idating the existing models that predict stroke in female
patients with atrial fibrillation had varied outcome rates
(1–6%) indicating differences between the data. Despite
the differences between the datasets there was consist-
ently moderate discriminative performance across the
databases.
Interpretation
Excluding patients with an anticoagulant after atrial fib-
rillation who did not have a prior stroke increased the
incidence rate for all databases except CCAE and
STRIDE. This suggests many people under 65 who have
a stroke within a year of initial atrial fibrillation diagno-
sis had a prior anticoagulant. This may be a consequence
of different treatment of patients with atrial fibrillation
who are under 65 compared to being 65 and older.
Atrial fibrillation patients who are given an anticoagu-
lant when they are younger than 65 may have other risk
factors prompting the use of an anticoagulant.
The sensitivity analysis shows the AUROC perform-
ance of models when removing patients with an anti-
coagulant and no stroke or an anticoagulant prior to
stroke is comparable or better, see Table 3. This makes
sense, for example consider the hypothetical situation
where a clinical risk model correctly assigns a high risk
to a patient who will have a stroke, but this high risk
leads to a clinician giving the patient anticoagulants be-
fore the stroke that prevent the stroke occurring. In this
situation the model’s performance will be negatively im-
pacted because of the intervention as the model was cor-
rect to assign a high risk but was wrong due to the
intervention preventing the stroke. This raises the issue
of how to fairly evaluate models that are already being
used clinically or in situations where existing guidelines
are used to identify patients who should being given pre-
ventative medicine. A fair evaluation is simple when
Table 3 The stroke rate (% of target population) across the datasets
Outcome rate % (Target population size)
Target Population CCAE MDCD MDCR Optum claims Optum EHR CUMC AUSOM STRIDE
T1: Females aged 65+ with atrial
fibrillation no prior stroke or
anticoagulants
– 4.95 (25,880) 4.40 (89,156) 4.07 (110,905) 1.30 (149,906) 5.75 (4312) 2.61 (268) 1.37 (3366)
T2: Females with atrial fibrillation
no prior stroke or anticoagulants
1.33 (61,224) 4.61 (33,262) – 3.49 (139,376) 1.13 (189,815) 5.00 (5758) 1.76 (455) 1.28 (4456)
Sensitivity T1: Females aged 65+
with atrial fibrillation no prior
stroke or anticoagulants
(no anticoagulants during tar)
– 5.04 (23,586) 5.26 (56,511) 4.48 (78,353) 1.44 (99,212) 6.23 (3403) 4.17 (144) 1.29 (2094)
Sensitivity T2: Females with atrial
fibrillation no prior stroke or
anticoagulants (no anticoagulants
during tar)
1.28 (46,054) 4.69 (29,546) – 3.73 (100,757) 1.22 (128,409) 5.35 (4546) 2.73 (256) 1.22 (2786)
Target population size in each dataset and the percentage of patients with stroke within 1 year of initial atrial fibrillation diagnosis
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there is no clinical intervention, but complex when pre-
ventative medicine exists for the outcome.
The validation performance of the models replicated
using the OHDSI patient-level prediction framework
and validated across the OHDSI network are comparable
with other published results. The Q-Stroke model per-
formed the worst out of all the existing models, but this
is likely due to many variables of that model being spe-
cific to the UK or are things that are missing from
claims data (such as family history, smoking status and
recent measurements). This may indicate that Q-Stroke
is not transportable to the US population. In addition,
the performances of the models were worse when ap-
plied to older females as age is a key predictor in many
of the models. In future work it would be interesting to
investigate applying more complex machine learning
methods with data-driven predictor selection to learn
more advanced models for predicting stroke in older pa-
tients with atrial fibrillation and no prior stroke.
Implications
The external validation was performed over 60 days by
five different research sites. Utilizing the OHDSI collab-
oration to validate a new prognostic model would enable
extensive external validation across diverse patient popu-
lations. In addition, this could be accomplished in sig-
nificantly less time than the current process for external
validation that takes more than 3 years on average for
one other researcher to implement the model [1]. The
large-scale external validation was only possible because
i) the OMOP common data model and OHDSI stan-
dardizations enable sharing of analysis code and ii) col-
laboration that is possible due to the OHDSI network.
We recommend researchers who develop prediction
models gain insight into their model’s transportability by
utilizing the OHDSI network’s external validation ability.
All that is required is to replicate their models using the
OHDSI Patient-level prediction framework, which would
also enable other researchers to readily implement the
model.
Limitations
The main limitation of this study was the correct repli-
cation of existing models. The reason external validation
rarely occurs is that many published models lack certain
details such as how to define variables, as code lists are
often not published. As a best practice patient-level pre-
diction models should provide full definitions for all var-
iables in the model and provide the model. We used the
model’s variable definitions when published, but when
these were not available, we used our own code sets to
define the variables. Another limitation in this study is
the limited target populations investigated. We chose fe-
males aged 65 or older with no prior stroke as that was
the intersection of criteria used when developing the five
existing stroke models but we also wanted to see the im-
pact of restricting to older patients (as many models use
age as a variable), so we included a second target popu-
lation of all females with no prior stroke. In future work
it would be interesting to investigate the performances
of the models across many different target populations.
Finally, although OHDSI contains a large network of da-
tabases, it may not be possible to validate every predic-
tion model on each of the databases within the network.
For example, some databases may not contain the cri-
teria used to identify the target population (e.g., if the
target population required a specific measurement), may
not have certain predictors recorded or may not have
the outcome recorded (e.g., if the outcome requires an
inpatient record but the data only contain outpatient re-
cords). The databases may also have insufficient observa-
tion time (e.g., a model predicting 10-year risk of stroke
may not be suitably evaluated in US claims data such as
Optum claims where only 13% of patients have 5+ years
of observation). Future work needs to be done to investi-
gate how to interpret the results of external validation
across heterogeneous datasets.
Conclusion
In this paper we demonstrated the ability to scale-up ex-
ternal validation by using a collaborative network where
researchers share a common data structure. The existing
prediction models were validated on 9 databases across
5 sites within 2 months. We recommend that re-
searchers utilize the OHDSI network to externally valid-
ate their models at scale across multiple datasets to gain
insight into the generalizability and/or transportability of
their models.
In addition, the results show that the existing stroke in
atrial fibrillation models do not perform well at predict-
ing stroke in the target population of older females in
datasets we investigated. This prompts further research
into whether a better model can be developed.
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